Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.

CAS：868540-17-4
中文别名：卡菲佐米;(S)-2-((S)-2-(2-(2H-1,4-恶嗪-4(3H)-基)乙酰氨基)-4-苯基丁酰胺)-4-甲基-N-((S)-1-((S)-4-甲基-1-((R)-2-甲基环氧乙烷-2-基)-1-氧代戊烷-2-基氨基)-1-氧代-3-苯基丙-2-基)戊酰胺;卡非佐脒;卡菲佐咪;
英文别名：Carfilzomib (PR-171);(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide;Kyprolis;UNII-72X6E3J5AR;PR-171;
分子式：C40H57N5O7
分子量：719.91
精确质量：719.426
Psa：158.47
Logp：4.085

UNII：72X6E3J5AR

密度：1.162g/cm3
沸点：975.627ºC at 760 mmHg
闪点：543.84ºC
折射率：1.551

海关编码：2933790090